Anti-hyperglycaemic mechanisms of benfluorex in type II diabetes mellitus

Feo, Pierpaolo De; Bolli, Geremia B.; Lavielle, R.; Gregoris, P. De

doi:10.1002/dmr.5610090507

Cited by 14 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to the results of this study, benfluorex application was reduced TBARS level and MPO activity, but it was increased NO, GSH and AA levels. In the previous studies, benfluorex has been shown to reduce hepatic glucose production, ameliorate binding of insulin to its receptor, and increase aerobic glucose utilization in skeletal muscle (Bianchi et al, 1993;De Feo et al, 1993;Riccio et al, 1993;Kohl et al, 2002). Also, that has been showed that benfluorex affects the expression of genes encoding enzymes related to both glucose and fatty acid metabolism, resulting in inhibition of mitochondrial β-oxidation, that resulted reduces in gluconeogenesis (Kohl et al, 2002).…”

Section: Discussionmentioning

confidence: 98%

Benfloreks: Dost mu, Düşman mı? Deneysel Diyabette, Benfloreksin Beyindeki Oksidatif Olaylara Etkileri

Peker

Balabanli

Özer

et al. 2021

Journal of Anatolian Environmental and Animal Sciences

View full text Add to dashboard Cite

Benfluorex is a pharmacological agent with antidiabetic and antihyperlipidemic properties. In this study, the brain's oxidative and non-enzymatic antioxidant status in diabetic and benfluorex administrated diabetic rats have been investigated. For the experimental procedures, three groups of 18 Wistar albino rats were used to control diabetes (induced by streptozotocin), and benfluorex treated diabetic rats (benfluorex administration intragastric 50 mg/kg daily for 21 days). Brain NOx, TBARS, GSH, AA levels, and MPO activity were determined spectrophotometrically. Benfluorex administration was caused that decreased lipid peroxidation and MPO activity while increased non-enzymatic antioxidant and NOx levels. These results showed that benfluorex treatment positively affects lipid peroxidation and the nonenzymatic antioxidant status of the brain during diabetes..

show abstract

Section: Discussionmentioning

confidence: 98%

Benfloreks: Dost mu, Düşman mı? Deneysel Diyabette, Benfloreksin Beyindeki Oksidatif Olaylara Etkileri

Peker

Balabanli

Özer

et al. 2021

Journal of Anatolian Environmental and Animal Sciences

View full text Add to dashboard Cite

show abstract

Rational Treatment of the “Plurimetabolic Syndrome”

Tiengo¹,

Avogaro²,

Prato³

1995

Medical Science Symposia Series

View full text Add to dashboard Cite

Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients

2003

View full text Add to dashboard Cite

Six-month efficacy of benfluorex (Mediator) (150-450 mg/day) was assessed in a double-blind multicenter study vs. placebo or metformin hydrochloride (850-2550 mg/day). After a 2-month run-in period of strict dieting, 722 type 2 diabetic patients were randomized (1:2:2) to receive placebo (n=144), benfluorex (n=294) or metformin (n=284). After a 5-week dose-finding phase, the efficacy of benfluorex was compared with that of placebo (test for difference, main analysis) and metformin (non-inferiority test, secondary analysis) during a 6-month fixed-dose treatment. At entry after strict dieting, there was no difference between groups for HbA(1C) (placebo, 7.4%+/-1.5%; benfluorex, 7.7%+/-1.6%; metformin, 7.8%+/-1.6%) and fasting plasma glucose (FPG; placebo, 9.7+/-2.3 mmol/l; benfluorex, 10.0+/-2.0 mmol/l; metformin, 10.2+/-2.5 mmol/l). At the end of the dose-finding phase, mean doses were 2.71 tablets/day for placebo group, 2.65 tablets/day for benfluorex (397.5 mg/day) and 2.50 tablets/day for metformin (2125 mg/day). At the end of treatment, HbA(1C) level decreased by 0.60% ( p<0.001) in benfluorex patients while it increased by 0.50% ( p<0.001) with placebo (intent-to-treat analysis). The mean endpoint difference was -0.86% (SE, 0.17%; p<0.001). Mean endpoint difference in HbA(1C) between benfluorex and metformin was 0.28% (SE, 0.12%) [90% CI, 0.07 to 0.48] (non-inferiority test, p=0.037). Treatment with benfluorex was well tolerated; 39% of these patients reported one or more emergent adverse events (compared to 38% on placebo and 43% on metformin) and only two patients suffered a treatment-related, serious adverse event. This study demonstrates that benfluorex: (1) significantly reduces HbA1C and fasting plasma glucose when compared to placebo; (2) has a good safety profile; and (3) has relatively lower potency compared to metformin, although the non-inferiority test (equivalence limit for HbA(1C) of 0.5%) was significant.

show abstract

Anti-hyperglycaemic mechanisms of benfluorex in type II diabetes mellitus

Cited by 14 publications

References 15 publications

Benfloreks: Dost mu, Düşman mı? Deneysel Diyabette, Benfloreksin Beyindeki Oksidatif Olaylara Etkileri

Benfloreks: Dost mu, Düşman mı? Deneysel Diyabette, Benfloreksin Beyindeki Oksidatif Olaylara Etkileri

Rational Treatment of the “Plurimetabolic Syndrome”

Six-month efficacy of benfluorex vs. placebo or metformin in diet-failed type 2 diabetic patients

Contact Info

Product

Resources

About